Tempus AI, Inc. (TEM)

US — Healthcare Sector
Peers: DOCS  SNN  FMS  COO  MEDP  NBIX  HOLX  UHS  CNC  ICLR 

Automate Your Wheel Strategy on TEM

With Tiblio's Option Bot, you can configure your own wheel strategy including TEM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TEM
  • Rev/Share 6.3177
  • Book/Share 2.9028
  • PB 24.7282
  • Debt/Equity 1.6088
  • CurrentRatio 3.2755
  • ROIC -0.1025

 

  • MktCap 12307697477.0
  • FreeCF/Share -0.363
  • PFCF -193.8006
  • PE -61.5941
  • Debt/Assets 0.3581
  • DivYield 0
  • ROE -0.6796

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade TEM TD Cowen Buy Hold -- $88 Oct. 21, 2025
Initiation TEM Canaccord Genuity -- Buy -- $110 Oct. 20, 2025
Initiation TEM H.C. Wainwright -- Buy -- $90 Sept. 2, 2025
Initiation TEM BTIG Research -- Buy -- $60 April 21, 2025
Downgrade TEM JP Morgan Overweight Neutral $50 $55 Feb. 25, 2025
Downgrade TEM William Blair Outperform Market Perform -- -- Feb. 12, 2025
Resumed TEM TD Cowen -- Buy $58 $74 Feb. 5, 2025
Initiation TEM Wolfe Research -- Outperform -- $60 Dec. 13, 2024
Initiation TEM Guggenheim -- Buy -- $74 Dec. 9, 2024
Downgrade TEM BofA Securities Buy Neutral $45 $60 Oct. 2, 2024

News

Conflicting Signals: Tempus AI's Stock Market Rally
TEM
Published: February 17, 2025 by: MarketBeat
Sentiment: Positive

Tempus AI NASDAQ: TEM is a leader in precision medicine and artificial intelligence (AI) in the healthcare sector. Tempus AI's stock price has seen an increase, with gains of over 160% in the last month and almost 150% year-to-date, causing investors to surge in interest.

Read More
image for news Conflicting Signals: Tempus AI's Stock Market Rally
AI Roundup: 3 Explosive AI-Adjacent Stocks to Watch in 2025
BBAI, SOUN, TEM
Published: February 11, 2025 by: Schaeffers Research
Sentiment: Positive

Artificial Intelligence (AI) has dominated headlines to start the year, especially after President Donald Trump revealed a joint venture to invest "$500 billion, at least" for AI Infrastructure in the U.S. More recently, Chinese startup DeepSeek shook up the sector after its AI model beat out OpenAi -- at a significantly lower cost.

Read More
image for news AI Roundup: 3 Explosive AI-Adjacent Stocks to Watch in 2025
Cathie Wood Is Betting Big on These 2 AI Stocks
META, TEM
Published: February 10, 2025 by: 24/7 Wall Street
Sentiment: Positive

Cathie Wood's comeback could continue through the year as most of her Ark Invest funds come roaring back alongside the tech trade.

Read More
image for news Cathie Wood Is Betting Big on These 2 AI Stocks

About Tempus AI, Inc. (TEM)

  • IPO Date 2024-06-14
  • Website https://www.tempus.com
  • Industry Medical - Healthcare Information Services
  • CEO Eric P. Lefkofsky
  • Employees 2400

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.